CIK 0001815442
- Large accelerated filer
Kymera Therapeutics, Inc.
Sign in to watch- Ticker
- KYMR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 812992166
- Phone
- +1 857-285-5314
- Business address
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Former names
- Kymera Therapeutics, Inc.
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale Director sold 31,798 shares at an average $103.75 ($3,299,037)
- 4 Planned sale Director sold 478,198 shares at an average $94.72 ($45,293,294)
- 4 Planned sale Chief Business Officer sold 2,500 shares at $99.00 ($247,500)
- 4 Exercise or conversion Chief Financial Officer acquired 12,653 shares (option exercise)
- 4 Planned sale Chief Operating Officer sold 17,184 shares at an average $79.92 ($1,373,290)
- 4 Exercise or conversion Director acquired 1,000 shares (option exercise)
- 4 Exercise or conversion Chief Financial Officer acquired 15,000 shares (option exercise)
- 4 Planned sale Director sold 3,000 shares at $87.00 ($261,000)
- 4 Planned sale Chief Executive Officer sold 30,000 shares at an average $81.18 ($2,435,377)
- 4 Planned sale Director sold 6,000 shares at an average $89.96 ($539,772)
- 4 Planned sale Chief Operating Officer sold 300 shares at $90.00 ($27,000)
- 4 Planned sale Chief Business Officer sold 1,347 shares at $90.00 ($121,230)
- 4 Planned sale Chief Operating Officer sold 6,551 shares at an average $90.00 ($589,598)
- 4 Planned sale Director sold 9,494 shares at an average $90.01 ($854,539)
- 4 Planned sale Chief Business Officer sold 10,264 shares at an average $87.47 ($897,782)
- 4 Planned sale Director sold 12,000 shares at an average $85.39 ($1,024,660)
Page 2 of 15 · 296 filings